TARS · Tarsus Pharmaceuticals, Inc.
$69.20
+0.32 (+0.46%)
At close · Aug 14
Market Cap
$3.04B
Shares
43.88M
Tarsus Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Tarsus Pharmaceuticals, Inc. (TARS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$1.24M
−$15.70M
'21 Q3
21-11-29
▲2858.6%
$10.00M
−$13.60M
'22 Q4
23-03-13
▲363.8%
$2.50M
−$23.42M
'23 Q1
23-05-09
·
$1.87M
−$39.15M
'23 Q3
23-11-09
▲30.8%
$13.08M
−$41.90M
'23 Q4
24-02-27
▲1004.6%
$27.61M
−$35.73M
'24 Q1
24-05-08
·
$40.81M
−$33.29M
'24 Q2
24-08-08
▲2471.8%
$48.12M
−$23.42M
'24 Q3
24-11-13
▲407.9%
$66.41M
−$23.11M
'24 Q4
25-02-25
▲183.7%
$78.33M
−$25.12M
'25 Q1
25-05-01
▲151.5%
$102.66M
−$20.34M
'25 Q2
25-08-06
▲146.7%
$118.70M
−$12.59M
'25 Q3
25-11-04
▲128.4%
$151.67M
−$8.37M
'25 Q4
26-02-23
▲106.9%
$162.05M
−$6.97M
'26 Q1
26-05-06
LATEST
▲69.4%
$173.91M
−$18.55M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Confident tone
Alkeas Pharmaceuticals Acquisition / ALK-001
XDEMVI Commercial Performance
Pipeline and Pipeline Prioritization
Revenue
$173.91M
▲ 69.4% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference in New York
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-26
Stifel 2026 Virtual Ophthalmology Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Tarsus Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone
Xdemvy launch momentum and commercial performance
Prescriber depth and ECP adoption
TPO5 Lyme disease prevention program
Revenue
$162.05M
▲ 106.9% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Barclays 28th Annual Global Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-23
Tarsus Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone
Xdenby commercial momentum and peak sales outlook
Payor access and coverage
Seasonality and Q1 dynamics
Revenue
$151.67M*
▲ 128.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Tarsus Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
XdemV/Xtemy commercial launch performance
Direct-to-consumer campaign
Ocular rosacea pipeline
Revenue
$118.70M
▲ 146.7% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Tarsus Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
Xdemvy Commercial Launch
Demodex Blepharitis Market Expansion
DTC Campaign Performance
Revenue
$102.66M
▲ 151.5% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Tarsus Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone
XDEMVY commercial momentum
Pipeline expansion and Ocular Rosacea (TP-04)
Direct-to-consumer campaign
Revenue
$78.33M
▲ 183.7% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Tarsus Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
XDEMVY commercial launch and sales growth
Pipeline programs (Ocular Rosacea, TP-04, Lyme)
Direct-to-consumer advertising campaign
Revenue
$66.41M*
▲ 407.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Tarsus Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone
Sales force expansion and ECP engagement
XDEMVY launch and sales growth
Evidence generation and clinical data
Revenue
$48.12M
▲ 2471.8% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Tarsus Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone
XDEMVY launch momentum and sales growth
ECP adoption and prescriber base expansion
Sales force expansion and DTC campaign
Revenue
$40.81M
Diluted EPS
$-0.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Tarsus Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
ECP adoption and prescriber base
XDEMVY launch and sales
Sales force and commercial investment expansion
Revenue
$27.61M
▲ 1004.6% YoY Diluted EPS
$-1.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Tarsus Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
Payer coverage and gross-to-net
XDEMVY launch momentum
Demodex blepharitis patient opportunity
Revenue
$13.08M*
▲ 30.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Tarsus Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$1.87M
Diluted EPS
$-1.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Tarsus Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$2.50M
▲ 363.8% YoY Diluted EPS
$-0.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Tarsus Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$10.00M*
▲ 2858.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-29
Tarsus Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$1.24M
Diluted EPS
$-0.76
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Showing 1–19 of 19 earnings calls
Key facts
CIK
1819790
CUSIP
87650L103
13F (30d)
246 filings
243 filers
Visit website
Investor relations